ArticleBrain pathology (Zurich, Switzerland)2003
TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways.
Article in Brain pathology (Zurich, Switzerland), 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 71 citations in OpenAlex.
- Article
- Therapeutic Potential of Berberine in the Treatment of Glioma: Insights into Its Regulatory Mechanisms.Cellular and molecular neurobiology · 2021Review
- SB365,Molecules (Basel, Switzerland) · 2019Article
- Small-Molecule-Targeting Hairpin Loop of hTERT Promoter G-Quadruplex Induces Cancer Cell Death.Cell chemical biology · 2019Article
- Article
- Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells.Cancer biology & therapy · 2019Article
- Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma.Molecular oncology · 2016Article
- Review
- Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model.Molecular therapy oncolytics · 2016Article
- Nanoparticle-Mediated Target Delivery of TRAIL as Gene Therapy for Glioblastoma.Advanced healthcare materials · 2015Article
- Clinically applicable human adipose tissue-derived mesenchymal stem cells delivering therapeutic genes to brainstem gliomas.Cancer gene therapy · 2015Article
- A humanized leucine zipper-TRAIL hybrid induces apoptosis of tumors both in vitro and in vivo.PloS one · 2015Article
- The ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma.SpringerPlus · 2014Article
- Identification of death receptors DR4 and DR5 in HTB-12 astrocytoma cell lines and determination of TRAIL sensitivity.Journal of solid tumors · 2013Article
- Transcriptome analysis of glioma cells for the dynamic response to γ-irradiation and dual regulation of apoptosis genes: a new insight into radiotherapy for glioblastomas.Cell death & disease · 2013Article
- Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts.Cancer letters · 2011Article
- Heterogeneity of primary glioblastoma cells in the expression of caspase-8 and the response to TRAIL-induced apoptosis.Apoptosis : an international journal on programmed cell death · 2011Article
- Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP.Cancer investigation · 2011Article
- Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System.Clinical Medicine Insights. Oncology · 2011Article
- Novel HTS strategy identifies TRAIL-sensitizing compounds acting specifically through the caspase-8 apoptotic axis.PloS one · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Many malignant glioma cells express death receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), yet some of these cells are resistant to TRAIL. Here, we examined signaling events in TRAIL-induced apoptosis and searched for therapeutic agents that could overcome TRAIL resistance in glioma cells. TRAIL induced apoptosis through death receptor 5 (DR5) and was mediated by caspase-8-initiated extrinsic and intrinsic mitochondrial pathways in sensitive glioma cell lines. TRAIL also triggered apoptosis in resistant glioma cell lines through the same pathways, but only if the cells were pretreated with chemotherapeutic agents, cisplatin, camptothecin and etoposide. Previous studies suggested that this was due to an increase in DR5 expression in wild-type TP53 cells, but this mechanism did not account for cells with mutant TP53. Here, we show that a more general effect of these agents is to downregulate caspase-8 inhibitor c-FLIP(S) (the short form of cellular Fas-associated death domain-fike interleukin-1-converting enzyme-inhibitory protein) and up-regulate Bak, a pro-apoptotic Bcl-2 family member, independently of cell's TP53 status. Furthermore, we showed that TRAIL alone or in combination with chemotherapeutic agents, induced apoptosis in primary tumor cultures from patients with malignant gliomas, reinforcing the potential of TRAIL as an effective therapeutic agent for malignant gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.